Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate.
Endothelin-1 (ET-1) concentrations are increased in patients with diabetes mellitus, particularly those with diabetic retinopathy, or essential hypertension. We hypothesized that ET-1 might participate in the development and progression of diabetic microangiopathy. In this study, the effects of the angiotensin converting enzyme (ACE) inhibitor, enalapril maleate, on diabetic angiopathy were examined in streptozotocin (STZ)-induced diabetic (STZ-DM) rats by monitoring variations in renal function and ET-1 concentrations in blood and organ tissues. Significant increases in kidney weight and in concentrations of urinary albumin, N-acetyl-fl-d-glucosamidase (NAG) and serum ET-1 were observed in the STZ-DM rats as compared with the non-diabetic rats, and the concentration of ET-1 in the kidneys tended to be increased. Microscopic and electron microscopic analyses showed increased mesangial cell proliferation, matrix expansion and enlarged mesangial area in the kidney of the diabetic rats. After administration of the ACE inhibitor, increased concentrations of urinary albumin and NAG in the STZ-DM rats were reduced to the control values with a slight improvement in the electron microscopic changes. These data suggest that ET-1 may be involved in the development and progression of diabetic nephropathy and may explain, in part, why diabetes is liable to complicate hypertension. ACE inhibitor may help to restore diabetic nephropathy in the STZ-induced diabetic rats.
Itoh
Y
Y
Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
Imamura
S
S
Yamamoto
K
K
Ono
Y
Y
Nagata
M
M
Kobayashi
T
T
Kato
T
T
Tomita
M
M
Nakai
A
A
Itoh
M
M
Nagasaka
A
A
D000118:Acetylglucosaminidase / Q000652:urine; D000418:Albumins / Q000032:analysis; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003404:Creatinine / Q000097:blood; D003921:Diabetes Mellitus, Experimental; D003928:Diabetic Nephropathies / Q000378:metabolism* / Q000473:pathology; D004656:Enalapril / Q000494:pharmacology*; D019332:Endothelin-1 / Q000097:blood / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D007668:Kidney / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D009929:Organ Size; D051381:Rats; D017208:Rats, Wistar
D000418:Albumins; D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D019332:Endothelin-1; D004656:Enalapril; D003404:Creatinine; D000118:Acetylglucosaminidase